Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMARANTH study of AZD3293 in early Alzheimer's disease
2014-002601-38Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lanabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Alzheimer's Disease Assessment Scale – Cognitive subscale (ADAS-Cog13). Started Dec 2014; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-002601-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002601-38.